All In Biotech

Drug Trial Radar · NCT05267743

Study to Confirm the Safety and Efficacy of Tegoprazan in Patients With Healed Erosive Reflux Disease

A Multicenter, Double-blind, Randomized, Active-controlled Phase 4 Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients With Erosive Reflux Disease

Last checked: Nov 20, 2026Latest source record: Jul 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 218 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

218

Actual

Start

Feb 16, 2021

Primary completion

May 25, 2022

Study completion May 25, 2022

Sponsor

Lead sponsor
HK inno.N CorporationIndustry
Sponsor type
Industry
First posted
Mar 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to evaluate the efficacy and safety of Tegoprazan 50mg, compared to Lansoprazole 30mg in patients with healed erosive reflux disease confirmed by endoscopy following oral administration once daily(QD) of 2 weeks or 4 weeks.

Conditions

  • Erosive Reflux Disease

Interventions

  • Tegoprazan 50mg QDDrug

    Tegoprazan 50mg tablets will be orally administered, once daily, for up to 2 weeks or 4 weeks.

  • Lansoprazole 30mg QDDrug

    Lansoprazole 30mg tablets will be orally administered, once daily, for up to 2 weeks or 4 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 4 weeks cumulative ERD healing rate(%)Time frame: 4 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Wonkwang University Hospital

    Iksan, Muwang-ro 895, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.